alexa Joel Posener | Early Clinical Development at AstraZenec
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Joel Posener

Early Clinical Development at AstraZeneca Neuroscience Innovative Medicines (iMed), USA
Joel Posener, MD, is the Head of Clinical Development in the AstraZeneca Neuroscience Innovative Medicines unit, which is responsible for the company's discovery and early development efforts in psychiatry, neurology and pain. Dr. Posener is a board certified psychiatrist with more than 10 years of experience in each of academic medicine and the pharmaceutical industry. He has broad experience in drug development, encompassing Phases 1-3, clinical pharmacology, translational medicine, and multiple indications in psychiatry and neurology, including schizophrenia (psychosis and cognitive impairment), depression, bipolar disorder, Alzheimer Disease, Parkinson's Disease (symptomatic and disease modification), other movement disorders, pain (various types), and orphan diseases. In addition to his primary responsibility at AstraZeneca, Dr. Posener serves on the faculty at Temple University School of Medicine, where he is Clinical Professor of Psychiatry.
Research Interest
Psychiatry NeuroScience

An Evaluation of the Potential of Cytochrome P450 3A4-Mediated Drug- Drug Interactions with Desvenlafaxine Use

Alice Nichols, Yali Liang, Kyle Matschke, Jeff Paul, Jessica Behrle, Joel Posener, Alain Patat, Shannon Lubaczewski, Gabriel Braley and Tanya Ramey

Research Article: J Bioequiv Availab 2013, 5: 053-59

Pharmacokinetics, Pharmacodynamics, and Safety of Desvenlafaxine, a Serotonin-Norepinephrine Reuptake Inhibitor

Alice Nichols I, Jessica Behrle A, Virginia Parks, Lyette Richards S, Stephanie McGrory B, Joel Posener, Alain Patat and Jeffrey Paul

Research Article: J Bioequiv Availab 2013, 5: 022-030

Global Speakers in the subject

Global Experts in the subject

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version